Nutriband (NTRB) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nutriband (NTRB) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 28.8% versus a loss of 55.1%. Over five years, NTRB leads with a -11.2% price change compared with -74.9% for ONCY. Nutriband is the larger company by market cap ($80.8 million vs $73.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTRB | ONCY |
|---|---|---|
| Share price | $6.65 | $0.557 |
| Market cap | $80.84M | $73.03M |
| 1-day change | +9.92% | +2.31% |
| YTD return | +33.26% | -35.98% |
| 1-year return | -28.82% | -55.08% |
| 5-year return | -11.15% | -74.91% |
| EPS (TTM) | $-0.53 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.19 | $1.32 |
| 52-week low | $2.80 | $0.525 |
| Distance from 52-week high | -27.60% | -57.80% |
| Analyst consensus | none | buy |
| Avg. price target upside | +125.56% | +645.06% |
| Average volume | 63.36K | 1.08M |
| Shares outstanding | 12.16M | 131.12M |
| Employees | — | 29 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTRB has outperformed ONCY by 26.3 percentage points over the past year.
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Health Care · Industrial Specialties
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
NTRB vs ONCY FAQ
Which is bigger, Nutriband or Oncolytics Biotech?
Nutriband (NTRB) is larger, with a market capitalization of $80.84M compared with $73.03M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, NTRB or ONCY?
NTRB returned -28.82% over the past 12 months, compared with -55.08% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Nutriband and Oncolytics Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Nutriband and Biotechnology: Pharmaceutical Preparations for Oncolytics Biotech.